AIM
BIIB icon

Acrospire Investment Management’s Biogen BIIB Stock Holding History

Acrospire Investment Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-400
Closed -$109K – 2175
2017
Q1 		$109K Sell
400
-500
-56% -$141K 0.09% 269
2016
Q4 		$255K Buy
900
+100
+13% +$29.6K 0.1% 213
2016
Q3 		$250K Sell
800
-200
-20% -$59.2K 0.17% 69
2016
Q2 		$242K Sell
1,000
-200
-17% -$52.7K 0.18% 18
2016
Q1 		$312K Buy
+1,200
New +$317K 0.22% 18

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acrospire Investment Management's BIIB Position: Q2 2017 in Review

Acrospire Investment Management sold out of Biogen (BIIB) in Q2 2017, closing a stake of 400 shares — an estimated $109K sold.

Acrospire Investment Management first reported a position in BIIB in Q1 2016 and held it in 5 quarters. The position peaked at $312K in Q1 2016. 992 funds tracked by Wall St. Rank hold BIIB as of Q2 2017.

  • Acrospire Investment Management reported no remaining Biogen position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 400 Biogen shares in Q2 2017, an estimated $109K.
  • Acrospire Investment Management first reported a position in Biogen in Q1 2016 and held it in 5 quarters.
  • Acrospire Investment Management's Biogen position peaked at $312K in Q1 2016.
  • 992 funds tracked by Wall St. Rank held Biogen as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.